Skip to content

rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia

Repetitive Transcranial Magnetic Stimulation (rTMS) as a Probe of Episodic Memory (EM) Neurocircuitry in Schizophrenia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04182113
Acronym
rTMS-EM
Enrollment
25
Registered
2019-12-02
Start date
2019-11-08
Completion date
2022-06-30
Last updated
2023-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

schizophrenia, psychosis, early phase psychosis, rTMS

Brief summary

This will be a single site pilot study. 30 subjects with Early Phase Psychosis (EPP), defined as medical record documentation of the onset of clinically significant psychotic symptoms within the past ten years, will be enrolled. Prior to randomization (Session 1), subjects will undergo Functional Magnetic Resonance Imaging (fMRI) during Episodic Memory (EM) and Resting State (RS) paradigms. This baseline scan will also include a high-resolution structural sequence for neuronavigation purposes. Then on three separate days each occurring one-week apart, subjects will receive one session of inhibitory (1 Hertz \[Hz\]) Repetitive Transcranial Magnetic Stimulation (rTMS), one session of excitatory (20 Hz) rTMS, and one sham stimulation session targeting the precuneus. The order of the three interventions will be randomized. Immediately following each rTMS or sham session, subjects will undergo repeat fMRI during EM and RS paradigms. The investigators will also examine the effect of rTMS on EM performance.

Detailed description

In spite of existing work studying rTMS as a treatment modality in schizophrenia, there are no studies that have examined the effects of precuneus directed rTMS on either EM deficits or the neurocircuitry subserving EM in schizophrenia. It is also important to note that the vast majority of studies using rTMS in schizophrenia have examined chronic populations where confounds associated with prolonged duration of illness may be present. Early Phase Psychosis (EPP) is a desirable population to study because these individuals tend to have fewer psychiatric and physical comorbidities and less antipsychotic drug exposure, all of which are factors that may confound investigations of new treatment interventions for this illness. In light of the significant unmet medical need associated with schizophrenia and the grave clinical effect of disrupted EM in the illness, rTMS modulating the precuneus, and potentially EM circuitry, represents an unexplored and potentially novel potential treatment option. This study proposes to combine functional magnetic resonance imaging (fMRI) with inhibitory Low Frequency (LF) (1 Hz) and excitatory High Frequency (HF) (20 Hz) rTMS protocols to interrogate the effects of rTMS targeting the precuneus on: 1) precuneus activation during EM task performance; 2) functional connectivity between the precuneus and key EM circuitry, specifically the Dorsolateral Prefrontal Cortex (DLPFC), Anterior Cingulate Cortex (ACC), and hippocampus and 3) performance during an in-scanner scene encoding and recognition EM task. This study will provide vital preliminary data on target engagement informing future clinical trials seeking to utilize rTMS to treat EM impairment in schizophrenia. This is an important population for study because if effective, rTMS may represent a novel treatment for EM deficits in schizophrenia. This study will also seek to refine the understanding of the brain circuitry that mediates the potential pro-EM effects of rTMS through the use of fMRI at baseline and following the course of rTMS administration.

Interventions

DEVICE1 Hz rTMS Stimulation

rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

All patients will receive 1 Hz rTMS, 20 Hz rTMS, and Sham rTMS, in a randomized order.

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. Between 18 and 40 years of age 2. Within 10 years of illness onset as defined by entry into treatment for psychotic symptoms 3. Able to give informed consent 4. Willing and able to adhere to the study schedule 5. Structured Clinical Interview for DSM-5 (SCID-5) diagnosis of schizophrenia 6. Clinical stability defined by: 1. Subjects must not have experienced an exacerbation of their illness within 4 weeks prior to randomization, leading to an intensification of psychiatric care in the opinion of the investigator. Examples of intensification of care include, but are not limited to: inpatient hospitalization, day/partial hospitalization, outpatient crisis management, or psychiatric treatment in an emergency room AND 2. Antipsychotic treatment stability for at least 4 weeks prior to randomization (no change in antipsychotic dosing or addition of new antipsychotic medication)

Exclusion criteria

1. Lifetime history of a seizure, excluding febrile seizures and those induced by substance withdrawal 2. First degree relative with idiopathic epilepsy or other seizure disorder 3. History of significant neurological illness 4. History of head trauma as defined by a loss of consciousness or a post-concussive syndrome 5. Pregnant or breast feeding 6. Known intelligence quotient (IQ) \< 70 based on subject report 7. Current acute, serious, or unstable medical conditions 8. Metallic objects planted in or near the head, including implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, Transcutaneous Electrical Nerve Stimulation (TENS) unit, ventriculoperitoneal shunt, or cochlear implants 9. Contraindications to Magnetic Resonance Imaging (MRI) or otherwise unable to tolerate MRI procedures 10. History of electroconvulsive therapy 11. Subjects taking clozapine 12. Subjects who have participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the 4 weeks prior to randomization 13. Subjects considered a high risk for suicidal acts - active suicidal ideation as determined by clinical interview OR any suicide attempt in 90 days prior to screening 14. Current DSM-5 diagnosis of alcohol or drug use disorder (excluding nicotine or caffeine) 15. Subjects who require concomitant treatment with prohibited medication, as specified in Attachment 2

Design outcomes

Primary

MeasureTime frameDescription
Change in Precuneus Functional Activation1 dayChange in estimated beta coefficients for the Target vs. Foil contrast during scene recognition in the precuneus. Beta coefficients reflect the strength of the blood oxygen-level dependent (BOLD) signal during each condition.Target images are those previously shown to participants, and Foil images have not been previously shown, as participants indicate whether they have been shown images. A higher measure indicates that the intervention increased brain activity during recognition of previously shown scenes.
Precuneus Functional Connectivity1 dayBlood oxygen level dependent (BOLD) signal functional connectivity with the precuneus in the bilateral dorsolateral prefrontal cortex, hippocampus, and anterior cingulate cortex. Value is the mean Fisher's transform of the correlation of BOLD time-series in the precuneus with the BOLD time-series in other named regions. Higher values indicate greater connectivity with the precuneus following the intervention. Value of zero indicates no relationship (no connectivity). This value has no unit of measurement.
Performance During In-scanner Episodic Memory Task1 dayPercent accuracy (0-100%) on detecting whether an image shown during a scene recognition was among those shown during the previous five-minute session. Higher scores indicate better performance in recalling images.

Countries

United States

Participant flow

Participants by arm

ArmCount
rTMS Order 1
1 Hz rTMS stimulation first, then 20 Hz rTMS stimulation, then sham rTMS rTMS: Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 pulses. Subjects will receive one session of high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minutes. Sham: Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
4
rTMS Order 2
1 Hz rTMS stimulation first, then sham rTMS, then 20 Hz rTMS stimulation rTMS: Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 pulses. Subjects will receive one session of high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minutes. Sham: Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
5
rTMS Order 3
20 Hz rTMS stimulation first, then 1 Hz rTMS stimulation, then sham rTMS rTMS: Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 pulses. Subjects will receive one session of high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minutes. Sham: Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
4
rTMS Order 4
20 Hz rTMS stimulation first, then sham rTMS, then 1 Hz rTMS stimulation rTMS: Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 pulses. Subjects will receive one session of high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minutes. Sham: Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
4
rTMS Order 5
Sham rTMS first, then 1 Hz rTMS stimulation, then 20 Hz rTMS stimulation rTMS: Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 pulses. Subjects will receive one session of high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minutes. Sham: Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
3
rTMS Order 6
Sham rTMS first, then 20 Hz rTMS stimulation, then 1 Hz rTMS stimulation rTMS: Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 pulses. Subjects will receive one session of high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minutes. Sham: Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
4
Total24

Baseline characteristics

CharacteristicrTMS Order 2rTMS Order 3rTMS Order 4rTMS Order 5rTMS Order 6rTMS Order 1Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
5 Participants4 Participants4 Participants3 Participants4 Participants4 Participants24 Participants
Age, Continuous26 years
STANDARD_DEVIATION 3.08
26.5 years
STANDARD_DEVIATION 4.43
23.25 years
STANDARD_DEVIATION 3.59
26 years
STANDARD_DEVIATION 8.54
25.5 years
STANDARD_DEVIATION 2.38
24 years
STANDARD_DEVIATION 4.08
25.21 years
STANDARD_DEVIATION 4.08
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants0 Participants0 Participants1 Participants1 Participants4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
4 Participants3 Participants4 Participants3 Participants3 Participants3 Participants20 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
3 Participants3 Participants2 Participants1 Participants3 Participants1 Participants13 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants0 Participants0 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
White
1 Participants1 Participants2 Participants2 Participants1 Participants3 Participants10 Participants
Region of Enrollment
United States
5 participants4 participants4 participants3 participants4 participants4 participants24 participants
Sex: Female, Male
Female
1 Participants3 Participants0 Participants0 Participants1 Participants0 Participants5 Participants
Sex: Female, Male
Male
4 Participants1 Participants4 Participants3 Participants3 Participants4 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 240 / 240 / 24
other
Total, other adverse events
1 / 241 / 241 / 24
serious
Total, serious adverse events
0 / 240 / 240 / 24

Outcome results

Primary

Change in Precuneus Functional Activation

Change in estimated beta coefficients for the Target vs. Foil contrast during scene recognition in the precuneus. Beta coefficients reflect the strength of the blood oxygen-level dependent (BOLD) signal during each condition.Target images are those previously shown to participants, and Foil images have not been previously shown, as participants indicate whether they have been shown images. A higher measure indicates that the intervention increased brain activity during recognition of previously shown scenes.

Time frame: 1 day

ArmMeasureValue (MEAN)Dispersion
1 Hz rTMSChange in Precuneus Functional Activation0.0329 Beta coefficient change (Target vs Foil)Standard Deviation 0.112
20 Hz rTMSChange in Precuneus Functional Activation0.067 Beta coefficient change (Target vs Foil)Standard Deviation 0.203
ShamChange in Precuneus Functional Activation-0.010 Beta coefficient change (Target vs Foil)Standard Deviation 0.112
Comparison: Paired t-test comparing Target vs. Foil activity following 1Hz rTMS to Target vs. Foil activity following 20 Hz rTMS stimulation.p-value: 0.3295% CI: [-0.129, 0.044]t-test, 2 sided
Comparison: Paired t-test between Target vs. Foil activation following 1 Hz rTMS and Target vs. Foil activation following Sham stimulation..p-value: 0.2595% CI: [-0.03, 0.12]t-test, 2 sided
Comparison: Paired t-test between Target vs. Foil activity following 20 Hz rTMS and Target vs. Foil activity following Sham stimulation.p-value: 0.1395% CI: [-0.024, 0.181]t-test, 2 sided
Primary

Performance During In-scanner Episodic Memory Task

Percent accuracy (0-100%) on detecting whether an image shown during a scene recognition was among those shown during the previous five-minute session. Higher scores indicate better performance in recalling images.

Time frame: 1 day

ArmMeasureValue (MEAN)Dispersion
1 Hz rTMSPerformance During In-scanner Episodic Memory Task80.58 Percentage correctStandard Deviation 15.4
20 Hz rTMSPerformance During In-scanner Episodic Memory Task76.63 Percentage correctStandard Deviation 22.4
ShamPerformance During In-scanner Episodic Memory Task75.61 Percentage correctStandard Deviation 20
Comparison: Paired t-test of scene recognition performance accuracy following 1Hz rTMS to accuracy following 20 Hz rTMS.p-value: 0.295% CI: [-1.6, 6.9]t-test, 2 sided
Comparison: Paired t-test of scene recognition performance accuracy following 1Hz rTMS to accuracy following sham rTMS.p-value: 0.1795% CI: [-1.9, 9.9]t-test, 2 sided
Comparison: Paired t-test of scene recognition performance accuracy following 20Hz rTMS to accuracy following 20 Hz rTMS.p-value: 0.7795% CI: [-10.8, 8.2]t-test, 2 sided
Primary

Precuneus Functional Connectivity

Blood oxygen level dependent (BOLD) signal functional connectivity with the precuneus in the bilateral dorsolateral prefrontal cortex, hippocampus, and anterior cingulate cortex. Value is the mean Fisher's transform of the correlation of BOLD time-series in the precuneus with the BOLD time-series in other named regions. Higher values indicate greater connectivity with the precuneus following the intervention. Value of zero indicates no relationship (no connectivity). This value has no unit of measurement.

Time frame: 1 day

ArmMeasureValue (MEAN)Dispersion
1 Hz rTMSPrecuneus Functional Connectivity0.0657 Transformed correlation coefficientStandard Deviation 0.0394
20 Hz rTMSPrecuneus Functional Connectivity0.0482 Transformed correlation coefficientStandard Deviation 0.0322
ShamPrecuneus Functional Connectivity0.0566 Transformed correlation coefficientStandard Deviation 0.0441
Comparison: Paired t-test comparing precuneus connectivity following 1Hz rTMS to precuneus connectivity following 20 Hz rTMS stimulation.p-value: 0.03895% CI: [0.001, 0.034]t-test, 2 sided
Comparison: Paired t-test comparing precuneus connectivity following 1Hz rTMS to precuneus connectivity following 20 Hz rTMS stimulation.p-value: 0.4495% CI: [-0.015, 0.033]t-test, 2 sided
Comparison: Paired t-test comparing precuneus connectivity following 20Hz rTMS to precuneus connectivity following sham stimulation.p-value: 0.2595% CI: [-0.032, 0.009]t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026